Public Insurance Tied to Lower Cancer Survival in Young Patients
Findings seen among patients <40 years with bone or soft tissue sarcomas, regardless of disease stage.
Sarcoma
Functional Outcomes Near Preoperative Levels After Surgery for Adult Soft Tissue Sarcoma
An analysis of how functional outcomes are measured in patients with soft tissue sarcoma revealed the efficacy of salvage surgery, and a need to improve frequency of FO measurements.
Kaposi Sarcoma Treatment Gets Breakthrough Therapy Designation
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pomalyst (pomalidomide; Celgene) for the treatment of patients with Kaposi sarcoma.
Management of Recurrent Ewing Sarcoma: Challenges and Approaches
[OncoTargets and Therapy] This review addresses common questions facing the clinician and patient, and provide an update on new strategies for Ewing Sarcoma therapy.
Nontypical Formulation of Pazopanib Effective, and Safe With Diligent Monitoring
Two cases studies demonstrate whether crushed pazopanib is a feasible alternative for patients who cannot swallow the tablets whole.
Tumor Location, Histology Influence Clinical Outcomes of Primary Cardiac Sarcoma
A retrospective review revealed the association between tumor location, disease histology, and prognosis for patients with primary cardiac sarcoma.
Risk of Kaposi Sarcoma Supported by Its Evolving Clinicopathologic Characteristics
Antiretroviral therapy has led to a dramatic reduction in incidence of AIDS-related Kaposi sarcoma; however, changes in the disease may lead to a resurgence in its risk for people with HIV infection.
Prognostic Factors for Survival Among Patients With Primary Bone Sarcomas of Small Bones
[Cancer Management and Research] The prognostic values of overall survival and cancer-specific survival for bone sarcomas of the hands or feet were assessed using Cox proportional hazards regression model with univariate and multivariate analyses.
Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma
With median age of participants in clinical trials for soft-tissue sarcoma younger than most patients who develop the disease, these researchers sought to determine the prevalence of including persons older than 65 in clinical trials and the efficacy of first-line chemotherapy for STS in older patients.
Developments in the Management of Advanced Soft-tissue Sarcoma – Olaratumab in Context
[OncoTargets and Therapy] This review examines the rationale of olaratumab in the treatment of advanced soft-tissue sarcomas and its emerging role in clinical practice.
Want to read more?
Please login or register first to view this content.
Next post in Sarcoma
